Previous 10 | Next 10 |
BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibiti...
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibiti...
Praxis Precision Medicines, Inc. (PRAX) Q4 2021 Earnings Conference Call February 28, 2022, 8:30 AM ET Company Participants Marcio Souza – President and Chief Executive Officer Bernard Ravina – Chief Medical Officer Alex Kane – Vice President of Investor Relations and Cor...
The following slide deck was published by Praxis Precision Medicines, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Praxis Precision Medicines, Inc. 2022 Q4 - Results - Earnings Call Presentation
Praxis Precision Medicines press release (NASDAQ:PRAX): Q4 GAAP EPS of -$1.30. As of December 31, 2021, Praxis had $275.9 million in cash, cash equivalents and marketable securities, compared to $296.6 million in cash and cash equivalents as of December 31, 2020 For further details see: ...
PRAX-114 Phase 2/3 monotherapy MDD Aria Study topline results expected in June 2022 PRAX-944 Phase 2a ET topline results expected in May 2022; to include open-label and placebo-controlled withdrawal data PRAX-222 seamless study in SCN2A-DEE expected to initiate in 2Q22 ...
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibitio...
PRAX-562 demonstrated robust preclinical antiseizure activity and exhibited an improved preclinical tolerability profile compared to standard-of-care Praxis expects to initiate a Phase 2 trial in the first half of 2022 to explore the potential for PRAX-562 to treat rare DEEs ...
BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today ann...
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today ann...
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
Praxis Precision Medicines Inc. Website:
2024-07-26 13:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...